Evidence map›Paper›PMID 25938501›Full record

ArticlePloS one2015

Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa.

Jennifer A Gilbert, Elisa F Long, Ralph P Brooks, Gerald H Friedland, Anthony P Moll, Jeffrey P Townsend, Alison P Galvani, Sheela V Shenoi

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03537872 (PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03537872 nacompletednot on this mapstarted 2018, after this paper: background citation

PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)

TypeinterventionalSponsorColumbia UniversityRan2018 to 2019Enrolled248ConditionsHIVArmsMiner-Friendly (MF) Service Venues TB/HIV Integration Strategies, Public Sector (PS) Health Facilities TB/HIV Integration Strategies
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. HIV-associated tuberculosis.International journal of STD & AIDS · 2021
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Synergism between diabetes and human immunodeficiency virus in increasing the risk of tuberculosis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018
    Article
  14. Article
  15. Article
  16. HIV treatment cascade in tuberculosis patients.Current opinion in HIV and AIDS · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jennifer A GilbertDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, United States of America.
Elisa F LongAnderson School of Management, University of California Los Angeles, Los Angeles, CA, United States of America.
Ralph P BrooksDepartment of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America.
Gerald H FriedlandDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America; Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America.
Anthony P MollDepartment of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America; Church of Scotland Hospital, Tugela Ferry, KwaZulu-Natal, South Africa.
Jeffrey P TownsendDepartment of Biostatistics, Yale University, New Haven, CT, United States of America; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, United States of America; Program in Computational Biology and Informatics, Yale University, New Haven, CT, United States of America.
Alison P GalvaniDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, United States of America; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, United States of America; Program in Computational Biology and Informatics, Yale University, New Haven, CT, United States of America.
Sheela V ShenoiDepartment of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, United States of America.
Yale University · USUniversity of California, Los Angeles · US

Funding

Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI John Edward Pachankis · 2001 to 2026
$48.5M
Fogarty International Clinical Research Scholars Support Center @ Vanderbilt-AAMCR24TW007988 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2007 to 2011
$27.6M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR01DA015612 · NIDA · STANFORD UNIVERSITY · PI OWENS, DOUGLAS K · 2002 to 2017
$9.4M
Impacts of Individual and Social Behavior on Influenza Dynamics and ControlU01GM087719 · NIGMS · YALE UNIVERSITY · PI GALVANI, ALISON P, MEYERS, LAUREN ANCEL · 2009 to 2018
$6.3M
Drug Interactions in Substance Abusers with HIV InfectionR01DA025932 · NIDA · YALE UNIVERSITY · PI FRIEDLAND, GERALD H. · 2008 to 2012
$1.8M
Evaluating the social influences that impact vaccination decisionsU01GM105627 · NIGMS · YALE UNIVERSITY · PI GALVANI, ALISON P · 2013 to 2017
$1.6M
Community-Based Intensive Case Finding for HIV, TB, and MDR/XDR TB in Rural SouthK23AI089260 · NIAID · YALE UNIVERSITY · PI SHENOI, SHEELA · 2011 to 2015
$668k
CGH CDC HHS 1U01GH000524-01CGH CDC HHS U01 GH000524FIC NIH HHS R24 TW007988FIC NIH HHS R24TW007988NIAID NIH HHS 1K23AI089260NIAID NIH HHS K23 AI089260NIDA NIH HHS R01 DA015612NIDA NIH HHS R01DA015612NIDA NIH HHS R01 DA025932NIDA NIH HHS R01DA025932NIGMS NIH HHS 2U01GM087719NIGMS NIH HHS 5U01GM105627NIGMS NIH HHS U01 GM087719NIGMS NIH HHS U01 GM105627NIMH NIH HHS P30 MH062294
6 · The paper itself

Abstract

The WHO recommends integrating interventions to address the devastating TB/HIV co-epidemics in South Africa, yet integration has been poorly implemented and TB/HIV control efforts need strengthening. Identifying infected individuals is particularly difficult in rural settings. We used mathematical modeling to predict the impact of community-based, integrated TB/HIV case finding and additional control strategies on South Africa's TB/HIV epidemics. We developed a model incorporating TB and HIV transmission to evaluate the effectiveness of integrating TB and HIV interventions in rural South Africa over 10 years. We modeled the impact of a novel screening program that integrates case finding for TB and HIV in the community, comparing it to status quo and recommended TB/HIV control strategies, including GeneXpert, MDR-TB treatment decentralization, improved first-line TB treatment cure rate, isoniazid preventive therapy, and expanded ART. Combining recommended interventions averted 27% of expected TB cases (95% CI 18-40%) 18% HIV (95% CI 13-24%), 60% MDR-TB (95% CI 34-83%), 69% XDR-TB (95% CI 34-90%), and 16% TB/HIV deaths (95% CI 12-29). Supplementing these interventions with annual community-based TB/HIV case finding averted a further 17% of TB cases (44% total; 95% CI 31-56%), 5% HIV (23% total; 95% CI 17-29%), 8% MDR-TB (68% total; 95% CI 40-88%), 4% XDR-TB (73% total; 95% CI 38-91%), and 8% TB/HIV deaths (24% total; 95% CI 16-39%). In addition to increasing screening frequency, we found that improving TB symptom questionnaire sensitivity, second-line TB treatment delays, default before initiating TB treatment or ART, and second-line TB drug efficacy were significantly associated with even greater reductions in TB and HIV cases. TB/HIV epidemics in South Africa were most effectively curtailed by simultaneously implementing interventions that integrated community-based TB/HIV control strategies and targeted drug-resistant TB. Strengthening existing TB and HIV treatment programs is needed to further reduce disease incidence.

Indexed as

AdolescentAdultAnti-HIV AgentsAntitubercular AgentsHIV InfectionsHumansMiddle AgedSouth AfricaTuberculosisYoung AdultAnti-HIV AgentsAntitubercular Agents

Identifiers

PMID25938501
PMCPMC4418809
OpenAlexW1596810369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.